Analyst Price Target is $54.00
▲ +285.99% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Tarsus Pharmaceuticals in the last 3 months. The average price target is $54.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 285.99% upside from the last price of $13.99.
Current Consensus is
The current consensus among 4 contributing investment analysts is to buy stock in Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.